**Core Concept**
Acute asthma exacerbations require rapid bronchodilation and anti-inflammatory therapy. First-line treatment involves short-acting beta-2 agonists (SABAs) for immediate relief, anticholinergics to augment bronchodilation, and systemic corticosteroids to reduce airway inflammation.

**Why the Correct Answer is Right**
Salmeterol is a long-acting beta-2 agonist (LABA) used for maintenance therapy in chronic asthma, not for acute exacerbations. In acute asthma, rapid onset of action is essential, and salmeterol takes 15–30 minutes to act and is not suitable for immediate relief. In contrast, salbutamol (a SABA) acts quickly (within minutes), prednisolone reduces inflammation within hours, and ipratropium bromide provides fast, synergistic bronchodilation via muscarinic blockade.

**Why Each Wrong Option is Incorrect**
Option A: Prednisolone is a systemic corticosteroid used in acute asthma to reduce airway inflammation and prevent recurrence.
Option B: Salbutamol is a short-acting beta-2 agonist that provides rapid bronchodilation in acute asthma attacks.
Option D: Ipratropium bromide is a muscarinic antagonist that enhances bronchodilation in acute asthma, especially when combined with a beta-agonist.

**Clinical Pearl / High-Yield Fact**
Never use LABAs like salmeterol as first-line treatment in acute asthma—only SABAs (e.g., salbutamol) should be used immediately. LABAs are for long-term control, not acute relief. Using LABAs in an acute attack can lead to delayed bronchodilation and increased risk of adverse effects.

✓ Correct Answer: C. Salmeterol